|
|
Vol. 17.13 – 24 July, 2026
|
|
|
|
|
|
|
Investigators demonstrated continued dependency on ERG in metastatic prostate cancer and identify a druggable pocket within its N-terminal Pointed (PNT) domain. [Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Researchers identified ZNF263 as a transcriptional repressor that silences MHC-I by recruiting nucleosome-remodeling and deacetylase (NuRD) to the STAT1 promoter, reducing STAT1 and MHC-I expression.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
Scientists hypothesized that the addition of stereotactic body radiation therapy could enhance immune responses and improve treatment outcomes.
[Journal for Immunotherapy of Cancer]
|
|
|
|
|
|
The authors functionally characterized a novel docetaxel resistance-associated lncRNA in prostate cancer. They identified an uncharacterized lncRNA, termed HUDRPC, which was significantly upregulated in resistant cells and patient-derived tumor tissues.
[Cancer Letters]
|
|
|
|
|
|
ATGL-mediated lipolysis represents a promising therapeutic target in prostate cancer, with heightened sensitivity in tumours lacking metabolic flexibility to utilize alternative pathways.
[British Journal of Cancer]
|
|
|
|
|
|
Researchers showed that the rRNA m6A methyltransferase METTL5 was progressively upregulated during prostate cancer progression and was associated with poor patient survival.
[Oncogene]
|
|
|
|
|
|
Scientists revealed that the nuclear receptor subfamily 3 group C member 1 (NR3C1)-acyl-CoA synthetase long-chain family member 4 (ACSL4) axis regulates lipid peroxidation and promotes radioresistance. [Cancer Science]
|
|
|
|
|
|
|
|
The authors highlight that PSMA-targeting agents incorporate the O-(carboxymethyl)-L-tyrosine scaffold, a versatile linker that enhances binding affinity and optimizes pharmacokinetics. [Journal of Medicinal Chemistry]
|
|
|
|
|
|
|
|
Pfizer, Inc. announced that the US FDA accepted for Priority Review a supplemental New Drug Application for TALZENNA®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI®, an androgen receptor pathway inhibitor, for homologous recombination repair gene-altered mCSPC. [Pfizer, Inc.]
|
|
|
|
|
|
|
|
September 15-17, 2026 Boston, Massachusetts, United States
|
|
|
|
|
|
|
|
|
|
|
University of Cambridge – Cambridge, England, United Kingdom
|
|
|
|
|
|
|
Thomas Jefferson University – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
|
University of Louisville – Louisville, Kentucky, United States
|
|
|
|
|
|
|
CICF International, Inc. – Maryland, United States
|
|
|
|
|
|
|
UmeÃ¥ University – UmeÃ¥, Sweden
|
|
|
|
|
|